IP administration of Δ¹²-PGJ₃ eradicates FV-leukemia in mice. (A) Spleen weights of FV-infected mice treated with various doses of Δ¹²-PGJ₃ (mg/kg body weight). n = 10 per treatment group. Δ¹²-PGJ₃ treatment at the indicated dosage was started at 1 week after infection for a period of 7 days. *P < .05. Inset: representative spleens from each treatment group. UI indicates uninfected mice. (B) Analysis of LSCs (M34⁺Kit⁺Sca1⁺) in the spleens of FV-infected mice treated with Δ¹²-PGJ₃ or vehicle (Veh) control. (C) FV-CFU formation in Δ¹²-PGJ₃– and vehicle control–treated mice. *P < .001. (D) H&E staining of spleen sections from uninfected (left), FV-infected–vehicle treated (middle), and FV-infected– Δ¹²-PGJ₃–treated mice (right) on day 14 after infection. Small box indicated on each section on the left is magnified on the right side. Scale bars indicate 500 μm.